Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma.
Transfusion-related acute lung injury (TRALI) is an uncommon life-threatening complication of hemotherapy. It is hypothesized to be the result of two independent insults: the first related to the clinical status of the patient and the second to the infusion of biologic response modifiers within blood components. We present a case of TRALI in a patient who received high-dose Interleukin-2 (IL-2) as treatment for metastatic renal cell carcinoma, where IL-2 is speculated to have been the first insult and transfusion of platelet concentrate the second. This is the first reported case of TRALI complicating treatment with high-dose immunotherapy.
Medeiros
Bruno C
BC
Department of Medical Oncology/Hematology University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA. bruno.medeiros@uchsc.edu
Kogel
Karen E
KE
Kane
Madeleine A
MA
D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000628:therapy; D055370:Lung Injury; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017713:Platelet Transfusion / Q000009:adverse effects*
D007376:Interleukin-2